WIT DYNE(000915)

Search documents
华特达因(000915) - 华特达因调研活动信息
2022-11-21 15:42
1 证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------------|-----------------------------------------------------------------------------------------------------|-------| | 投 资 者 关 系活 \n动 类别 | ■特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n□现场参观 □其他 | | | 参 与 单 位 名称 及人员姓名 | 1.光大证券 林小伟 黄素青 | | | | 上投摩根基金 蔡云翔 | | | | 融通基金 杨有为 | | | | 阳光资产 赵孟甲 | | | | 宝盈基金 谢燕萍 | | | | 安信基金 徐衍鹏 | | | | 长信基金 何增华 | | | | .天弘基金 王斌、郭相博、刘盟盟 | | | | .新华养老 牛悦 | | | | .华泰资产 王金成 | | | | 、华泰柏瑞 谢峰 ...
华特达因(000915) - 华特达因调研活动信息
2022-11-21 05:34
证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号:2022-002 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...
华特达因(000915) - 华特达因调研活动信息
2022-11-21 05:30
证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号:2022-001 | --- | --- | --- | |----------------|----------------------------------|---------------------------------------------------------------------------------------------------| | | | | | | 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | □其他 | | | 光大证券 林小伟 黄素青 | 招商信诺 詹孝颖 | | | 兴证资管 | 刁举鹏 喜世润投资 张北亚 | | | 万家基金 | 杨梦朝 泰康基金 刘勍 | | 参与单位名称及 | 太平基金 | 闫庚威 睿骏资产 魏志华 | | 人员姓名 | 融通基金 杨有为 | 人寿资产 邓文强 | | | 聚铭基金 | 王广群 汇华资本 张桂柱 | | | 嘉 ...
华特达因(000915) - 华特达因调研活动信息
2022-11-17 14:31
证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号:2022-011 | --- | --- | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------------|-------------|--------------------------------------------------------| | | | | | | | 特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | □现场参观 | □其他 | | | | 光大证券组织的电话会议。参加人员主要如下: | | | | | 光大证券:杜传文 林小伟 | 黄素青 | lygh capital :阙振洋 | | | 博时基金:张弘 工银瑞信:张杭 光 ...
华特达因(000915) - 华特达因调研活动信息
2022-11-17 14:31
1 证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号:2022-010 | --- | --- | --- | --- | --- | --- | |----------------|--------------------------------------------|-------------|------------|---------------------------------------------|----------------| | | | | | | | | 投资者关系活动 | 特定对象调研 | | | □分析师会议 | | | | □媒体采访 | | | □业绩说明会 | | | 类别 | □新闻发布会 | | | □路演活动 | | | | □现场参观 | | □其他 | | | | | 兴业证券组织的电话会议。参加人员主要如下: | | | | | | | | | | 兴业证券 孙媛媛、董晓洁 中国民生信托 景莹 | | | | 真脉 | Iris Wang、 | Lisa Jiang | 易米基金 刘梦杨、包丽华 | | | | ...
华特达因(000915) - 山东辖区上市公司2022年度投资者网上集体接待日活动信息
2022-11-17 07:54
编号:2022-014 证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | □分析师会议 \n 业绩说明会 \n□路演活动 \n 其他 | | 参与单位名称及 人员姓名 | 参加山东辖区上市公司 资者 | 2022 年度投资者网上集体接待日的投 | | 时间 | 2022 年 11 月 16 日 | 14:00-16:00 | | 方式 | 全景网"投资者关系互动平台"( | https://ir.p5w.net ) | | 上市公司 ...
华特达因(000915) - 参与投资者网上集体接待日活动的公告
2022-11-11 07:41
证券代码:000915 证券简称:华特达因 公告编号:2022-031 山东华特达因健康股份有限公司 关于参加山东辖区上市公司 2022 年度投资者网上集 体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整,没有虚假记载、误导性陈述或重大遗漏。 为加强与广大投资者的沟通交流,山东华特达因健康股份有限 公司(以下简称"公司")将参加由山东证监局、山东上市公司协会 联合举办的山东辖区上市公司 2022 年度投资者网上集体接待日活 动,现将有关事项公告如下: 一、 活动时间 2022 年 11 月 16 日(星期三)14:00 至 16:00。 二、活动方式 本次投资者网上集体接待日活动将通过全景路演平台进行线上 交 流 。 投 资 者 可 以 登 录 全 景 网 " 投 资 者 关 系 互 动 平 台 " (http://ir.p5w.net/)参与本次活动。 三、公司出席本次活动人员 董事会秘书范智胜先生、财务总监王伟女士、会计机构负责人刘 稳女士、证券事务代表王春阳先生将参加本次投资者网上集体接待日 活动,与投资者进行在线交流。欢迎广大投资者积极参与。 特此公告 山东华特达因健康股 ...
华特达因(000915) - 华特达因调研活动信息(2)
2022-10-24 05:04
证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号:2022-013 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|----------------------------------------------------|--------------|-------|-----------------------------------------------|-------|--------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | \n \n | | □分析师会议 \n□业绩说明会 \n□路演活动 \n□其他 | | | | | | | | 国海证券组织的电话会议。参加人员主要如下: | | | | | 国海证券 | 周小刚、郭磊 | | | | | | | 安信基金 | 英正达 | | 北京诺昌投资 | | 许耀文 | | | 博道基金 | 邓韵阳 | | 北京远惟投资 | | 张翠双 | | | | | ...
华特达因(000915) - 华特达因调研活动信息(1)
2022-10-24 05:04
证券代码:000915 证券简称:华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 1 编号:2022-012 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------|------------------------------------------------------|---------|-------|--------------------------------------------|---------------------------------------|-------------------|-----------|--------| | 投资者关系活动 \n类别 | 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 | \n | | □其他 | □分析师会议 \n□业绩说明会 \n□路演活动 | | | | | | | | | 光大证券组织的电话会议。参加人员主要如下: | | | | | | | 光大证券研究所 | | | 林小伟、黄素青 | | | ...
华特达因(000915) - 2022 Q3 - 季度财报
2022-10-19 16:00
Financial Performance - For the first nine months of 2022, the company achieved a revenue of CNY 1.819 billion, representing a year-on-year growth of 15.67%[5] - The net profit attributable to shareholders for the same period was CNY 462 million, an increase of 45.10% compared to the previous year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported a revenue of CNY 526 million in Q3 2022, up 33.58% year-on-year, and a net profit of CNY 283 million, which is a 68.83% increase[5] - The net profit for the first nine months was CNY 865 million, a 46.22% increase driven by growth in the pharmaceutical business[15] - The net profit for the third quarter was 865,038,482.33 CNY, an increase of 46.1% compared to 591,605,152.82 CNY in the same period last year[30] - The total comprehensive income attributable to the parent company's owners was 462,412,455.71 CNY, compared to 318,686,318.58 CNY in the previous year, reflecting a growth of 45%[30] - The company reported a total profit of 1,009,123,751.74 CNY, up from 693,224,944.16 CNY year-over-year, representing a 45.5% increase[30] Assets and Liabilities - The total assets of the company at the end of the reporting period reached CNY 4.595 billion, a growth of 16.76% from the end of the previous year[7] - Total liabilities rose to CNY 666,435,393.06, compared to CNY 536,028,235.88, marking an increase of 24.3%[26] - The equity attributable to shareholders increased to CNY 2.520 billion, reflecting a year-on-year growth of 12.25%[7] - The equity attributable to shareholders increased to CNY 2,519,636,676.14 from CNY 2,244,689,408.43, a growth of 12.2%[26] - The company's retained earnings reached CNY 2,094,102,952.03, up from CNY 1,819,155,684.32, reflecting an increase of 15.1%[26] Cash Flow and Investments - The net cash flow from operating activities for the first nine months was CNY 945 million, showing a growth of 55.40% year-on-year[7] - Cash flow from operating activities generated a net amount of 945,513,109.09 CNY, compared to 608,444,452.56 CNY in the same period last year, indicating a 55.4% increase[33] - Investment activities resulted in a net cash outflow of 98,191,382.59 CNY, an improvement from a net outflow of 962,673,685.57 CNY in the same period last year[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,742[16] - Shandong Huate Holding Group Co., Ltd. holds 22.00% of shares, totaling 51,544,340 shares[16] - Hong Kong Central Clearing Limited holds 3.03% of shares, totaling 7,106,965 shares[16] - The company has a total of 10 major shareholders, with the top 10 holding significant stakes[16] - The company has not reported any pledged or frozen shares among the top shareholders[16] - The report indicates no known relationships or concerted actions among the major shareholders[19] Operational Highlights - Total operating revenue for the third quarter was CNY 1,818,732,732.71, an increase of 15.7% compared to CNY 1,572,409,826.06 in the same period last year[26] - Total operating costs decreased to CNY 831,485,865.51 from CNY 906,185,041.84, representing a reduction of approximately 8.2%[26] - The company reported a significant increase in accounts receivable by 70.73% to CNY 101 million, attributed to the growth in sales revenue[12] - The company’s contract liabilities rose by 73.88% to CNY 190 million, indicating an increase in advance payments received[15] - The company reported a significant increase in accounts payable, which rose to CNY 32,729,985.06 from CNY 70,563,649.54, indicating a decrease of 53.7%[23] Future Plans - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[28] Earnings Per Share - The basic earnings per share for Q3 2022 was CNY 0.67, marking a 76.36% increase compared to the same period last year[7] - Basic and diluted earnings per share were both 1.97 CNY, up from 1.36 CNY year-over-year[32]